On Mar. 18, 2020, Entos Pharmaceuticals announced their development of a Fusogenix DNA vaccine to prevent COVID-19 infections. Entos ﾒFusogenix Platform is a proteo-lipid vehicle (PLV) that uses a novel fusion mechanism to deliver its genetic payload directly inside cells. Entos has developed unique formulations to effectively deliver a wide range of genetic therapies, including plasmid DNA.